Portfolio Rapha Capital Management

Preliminary Results from NexImmune’s Phase 1/2 Trial of NEXI-001 in AML Presented at 62nd ASH Annual Meeting and Exposition

By Kevin SlawinDecember 7, 2020February 4th, 2021No Comments

NexImmune Inc.
Preliminary Results from NexImmune’s Phase 1/2 Trial of NEXI-001 in AML Presented at 62nd ASH Annual Meeting and Exposition
Initial data demonstrate early signs of safety, tolerability and robust immune responses in acute myeloid leukemia (AML) patients with relapsed disease after allogeneic hematopoietic cell transplantation (allo-HSCT)
December 7, 2020

Previous PostNexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&D and Jeffrey Weber as Chief Scientific Advisor
Next PostRapha Capital Management Participates in Series D Financing for Poseida Therapeutics

© 2024 Ponce Therapeutics. Privacy Policy | Terms & Conditions